Accumulating evidence from multitudinous studies has shown that aberrant expression and activation of STAT3 is implicated in tumor progression, drug resistance and metastasis of various human cancers including NSCLC6, 12, 13, suggesting that STAT3 may contribute to resistance to prevailing chemotherapy in NSCLC. This evidence concerns the gene STAT3 and cancer.